The direct-to-consumer laboratory-developed test detects six cancer types with 97% sensitivity and specificity using microRNA biomarkers.
California-based Yenos Analytical has launched the Yenos Test, a multi-cancer early detection urine test that claims to detect stage I/II cancers with high accuracy.
The test is available for direct consumer ordering through the company’s website for $749 and may be eligible for health savings account reimbursement.
The laboratory-developed test uses microRNA quantification and nanopore-array detection technology to identify signals from six cancer types: prostate, pancreatic, lung, breast, ovarian, and colorectal cancers. These cancers account for approximately 50% of annual US cancer diagnoses and include some with the highest mortality rates. Recent studies with healthy samples and cancer samples from newly diagnosed stage I/II patients with prostate, pancreatic, lung, breast, ovarian, and colorectal cancer showed a 97% sensitivity and 97% specificity.
“These exceptional results are attributed to using microRNA cancer biomarkers evaluated in hundreds of thousands patients over the last 25 years since the discovery of their regulatory functions,” says Dr Anastassia Kanavarioti, founder and CEO of Yenos Analytical, in a release.
The test is designed for non-pregnant women and individuals aged 30-80 with no known cancer diagnosis in the past three years. Patients collect urine samples at home and ship them via FedEx to the company’s California laboratory for analysis. Results are delivered through an online patient portal.
Addressing Screening Gaps
According to Yenos Analytical, nine in 10 Americans have delayed health checkups and screenings, while seven out of 10 annual cancer cases and deaths in the US occur in cancers with no recommended screening protocols.
“The Yenos cancer test offers an answer to everyone who takes it. A piece of mind that one is cancer free, or a warning that cancer may be present and that a visit with a primary physician is warranted,” says Kanavarioti in a release.
The company notes that microRNA biomarker literature suggests the test methodology may identify virtually all cancer types, including brain cancer, which cannot be detected by DNA- or protein-derived biomarkers.
ID 54807494 © Jarun011 | Dreamstime.com
